The Association of Statin Therapy with Liver and Pancreatic Fat Fraction in Type 2 Diabetes Mellitus

被引:0
|
作者
Parlar, Mehmet Akif [1 ]
Mutlu, Hakan [1 ]
Dogantekin, Betul [1 ]
Musaoglu, Ismail Serhat [1 ]
Albayrakoglu, Nisa Demirbosnak [1 ]
Yavuz, Mustafa Lutfi [2 ]
Ozbolat, Zehra Busra [3 ]
Kaplan, Mustafa [1 ]
机构
[1] Univ Hlth Sci, Sultan Abdulhamid Han Training & Res Hosp 2, Dept Internal Med, Tibbiye St, TR-34668 Istanbul, Turkiye
[2] Istanbul Univ, Fac Med, Dept Cardiol, TR-34093 Istanbul, Turkiye
[3] Cerkezkoy State Hosp, Dept Chest Dis, Tekirdag Prov Hlth Directorate, TR-59100 Tekirdag, Turkiye
关键词
diabetes mellitus; fatty pancreas; fatty liver; statin; steatosis; ADIPOSE-TISSUE INFLAMMATION; INSULIN-SECRETION; GLUCOLIPOTOXICITY; CHOLESTEROL; DYSFUNCTION; DISEASE; ATORVASTATIN; SIMVASTATIN; STEATOSIS; EFFICACY;
D O I
10.3390/diagnostics15040426
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Objectives: It has been shown that the use of statins in patients with type 2 diabetes mellitus (T2DM) worsens hyperglycemia and hemoglobin A1c levels but may help in the preservation of pancreatic beta-cell function. The potential role of a high pancreatic fat fraction (PFF) in this process has not yet been clarified. This study aimed to investigate whether the liver fat fraction (LFF) and PFF in T2DM patients is affected by statin therapy. Methods: This cross-sectional study involved a total of 140 T2DM patients, including both those who were receiving (n = 70) and those who were not receiving (n = 70) statin therapy. The mapping of the LFF and PFF utilizing the IDEAL-IQ sequence was conducted in magnetic resonance imaging. Results: In T2DM patients who used statins, the median PFF was higher compared to those who did not use statins (8.4 vs. 6.2%, p = 0.021), while the median LFF was found to be similar (8.4 vs. 8.9, p = 0.572). Variations in PFF were associated with the use of various statins (non-statin group: 6.2 vs. atovastatin: 8.7 vs. rosuvastatin: 3.2 vs. pitavastatin: 9.2, p = 0.004). The multivariable regression analysis indicated that insulin usage decreased log(LFF) by a factor of 0.16-fold (beta +/- SE = -0.16 +/- 0.05, p = 0.010), and rosuvastatin usage reduced log(PFF) by 0.16-fold (beta +/- SE = -0.16 +/- 0.07, p = 0.025), irrespective of other risk factors. Furthermore, the use of atorvastatin (beta +/- SE = 0.17 +/- 0.06, p = 0.011) and pitavastatin (beta +/- SE = 0.19 +/- 0.07, p = 0.008) were independently associated with an increase in log(PFF). Conclusions: In patients with T2DM, statin use did not show a significant effect on the liver fat fraction, but it caused differences in the pancreatic fat fraction. The observation of a lower pancreatic fat fraction in patients taking a rosuvastatin and atorvastatin dose of 40 mg/day suggests that different types and doses of statins may have varying effects on pancreatic fat accumulation.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Association of pancreatic fat content with type II diabetes mellitus
    Nadarajah, C.
    Fananapazir, G.
    Cui, E.
    Gichoya, J.
    Thayalan, N.
    Asare-Sawiri, M.
    Menias, C. O.
    Sandrasegaran, K.
    CLINICAL RADIOLOGY, 2020, 75 (01) : 51 - 56
  • [2] Lipid metabolism in type 2 diabetes mellitus and statin therapy
    Yamada, Nobuhiro
    ENDOCRINE JOURNAL, 2010, 57 : S204 - S204
  • [3] Association between type 2 diabetes mellitus and body composition based on MRI fat fraction mapping
    An, Qi
    Zhang, Qin-He
    Wang, Yue
    Zhang, Han-Yue
    Liu, Yu-Hui
    Zhang, Zi-Ting
    Zhang, Mei-Ling
    Lin, Liang-Jie
    He, Hui
    Yang, Yi-Fan
    Sun, Peng
    Zhou, Zhen-Yu
    Song, Qing-Wei
    Liu, Ai-Lian
    FRONTIERS IN PUBLIC HEALTH, 2024, 12
  • [4] Abrogating the Induction of Type 2 Diabetes Mellitus Secondary to Statin Therapy
    Planchon, Sarah M.
    CARDIOVASCULAR DRUGS AND THERAPY, 2014, 28 (05) : 393 - 394
  • [5] Sympathetic Transduction in Type 2 Diabetes Mellitus Impact of Statin Therapy
    Young, Benjamin E.
    Holwerda, Seth W.
    Vranish, Jennifer R.
    Keller, David M.
    Fadel, Paul J.
    HYPERTENSION, 2019, 74 (01) : 201 - 207
  • [6] PANCREATIC FAT CONTENT PLAYS AN IMPORTANT ROLE IN THE DEVELOPMENT OF TYPE 2 DIABETES MELLITUS SIMILAR TO THAT OF LIVER FAT CONTENT
    Ting, L.
    Liyun, W.
    Zheng, W.
    Cao, Z.
    ACTA ENDOCRINOLOGICA-BUCHAREST, 2023, 19 (04) : 421 - 425
  • [7] Effect of Vildagliptin and Metformin Combination Therapy on Liver Fat Content in Type 2 Diabetes Mellitus
    Chen, Zaoping
    Liu, Jun
    Hang, Xinmei
    DIABETES, 2015, 64 : A508 - A508
  • [8] THE ASSOCIATION OF SOLUBLE ENDOGLIN AND ENDOTHELIAL DYSFUNCTION IN TYPE 2 DIABETES MELLITUS AND FAMILIAL HYPERCHOLESTEROLEMIA: IMPACT OF STATIN THERAPY
    Lasticova, M.
    Visek, J.
    Blaha, V.
    Blaha, M.
    Liptak, V.
    Nachtigal, P.
    ATHEROSCLEROSIS, 2022, 355 : E86 - E86
  • [9] Association of Statin Medications on Development of De Novo Hepatocellular Carcinoma in Patients With Liver Cirrhosis and Diabetes Mellitus Type 2
    Verduzco, Esteban
    Chung, Raymond
    Yeh, Heidi
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S1163 - S1164
  • [10] Quantitative Assessment of Pancreatic Fat by Quantitative CT in Type 2 Diabetes Mellitus
    Li, Zhizhen
    Yue, Qingmei
    Chen, Yunjin
    Zhang, Yifan
    Wan, Yamin
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2022, 15 : 7977 - 7984